Research Article
Mesenchymal Stem Cells: A New Choice for Nonsurgical Treatment of OA? Results from a Bayesian Network Meta-Analysis
Table 2
The details of SURCA and mean rank of safety endpoints.
| | Treatment | OR (95% CI) for withdrawal due to AEs | SURCA for withdrawal due to AEs (%) | Mean rank for withdrawal due to AEs | OR (95% CI) for serious AEs or death | SURCA for serious AEs or death (%) | Mean rank for serious AEs or death | OR (95% CI) for injection site discomfort | SURCA for injection site discomfort (%) | Mean rank for injection site discomfort |
| | Placebo | Reference | 57.8 | 2.7 | Reference | 60.8 | 2.6 | Reference | 86.0 | 1.6 | | MSCs | -0.15 (-4.22, 3.93) | 56.3 | 2.7 | 0.20 (-1.70, 2.10) | 42.7 | 3.3 | 0.31 (-2.07, 2.68) | 66.5 | 2.3 | | PRP | 0.14 (-1.43, 1.70) | 48.0 | 3.1 | 1.24 (0.29, 2.19) | 39.1 | 3.4 | 0.34 (-1.02, 1.70) | 11.8 | 4.5 | | HA | -0.05 (-0.74, 0.64) | 62.2 | 2.5 | 0.89 (0.30, 1.47) | 32.4 | 3.7 | 0.40 (-0.43, 1.23) | 32.6 | 3.7 | | GCs | 0.50 (-0.64, 1.63) | 25.8 | 4.0 | 0.55 (-0.49, 1.59) | 75.0 | 2.0 | -0.54 (-2.58, 1.49) | 53.2 | 2.9 |
|
|
